Abstract: The invention relates to antibodies that bind to VEGFR-2. The antibodies are used for treating neoplastic diseases, hyperproliferative disorders, and angiogenic disorders and can be used alone or in combination with other agents.
Abstract: The invention provides antibodies that specifically bind to PD-L1 and fusion molecules comprising PD-L1 binding proteins constructed with an IL15 receptor-binding domain, nucleic acid molecules encoding the same, and therapeutic compositions thereof. The agents inhibit PD-L1-mediated immunosuppression and enhance cell and cytokine mediated immunity for the treatment of neoplastic and infectious diseases.
Type:
Grant
Filed:
January 15, 2015
Date of Patent:
September 10, 2019
Assignee:
KADMON CORPORATION, LLC
Inventors:
Samuel D. Waksal, Zhenping Zhu, Yan Wu, Stella Martomo, Zhaojing Zhong, Dan Lu
Abstract: The invention relates to antibodies that bind to VEGFR-2. The antibodies are used for treating neoplastic diseases, hyperproliferative disorders, and angiogenic disorders and can be used alone or in combination with other agents.
Type:
Grant
Filed:
June 14, 2018
Date of Patent:
July 30, 2019
Assignee:
Kadmon Corporation, LLC
Inventors:
Zhenping Zhu, Dan Lu, Zhanna Polonskaya
Abstract: The invention relates to inhibitors of ROCK1 and/or ROCK2. Also provided are methods of treating diseases and disorders involving inhibiting ROCK1 and/or ROCK2.
Type:
Grant
Filed:
November 10, 2017
Date of Patent:
January 22, 2019
Assignee:
Kadmon Corporation, LLC
Inventors:
Masha Poyurovsky, Ji-In Kim, Kevin Liu, Alexandra Zanin-Zhorov
Abstract: The invention provides novel inhibitors of ROCK1 and/or ROCK2. Also provided are methods of treating diseases and disorders involving inhibiting ROCK1 and/or ROCK2. The present invention includes pharmaceutical compositions comprising the compounds of the invention and a pharmaceutically acceptable carrier and/or diluents. The present invention includes compositions comprising a substantially pure compound of the invention and a pharmaceutically acceptable salt, steroisomer, or hydrate thereof: and a pharmaceutically acceptable excipient and/or diluents.
Type:
Grant
Filed:
October 7, 2014
Date of Patent:
November 13, 2018
Assignee:
KADMON CORPORATION, LLC
Inventors:
Ji-in Kim, Kevin Liu, Masha Poyurovsky, Dan Lu, Zhenping Zhu
Abstract: Provided herein are compounds that modulate glucose uptake activity and are useful for treating cancer, autoimmune diseases, inflammation, infectious diseases, and metabolic diseases. In certain embodiments, the compounds modulate glucose uptake activity by modulating cellular components, including, but not limited to those related to glycolysis and known transporters/co-transporters of glucose such as GLUT1 and other GLUT family members/alternative hexose transporters. In certain embodiments, the compounds have the structure of formula I: Formula (I) wherein the variables have the values disclosed herein.
Type:
Application
Filed:
June 24, 2016
Publication date:
October 18, 2018
Applicant:
Kadmon Corporation LLC
Inventors:
Kellen Olszewski, Ji-Ln Kim, Masha Poyurovsky, Kevin G. Liu, Anthony Barsotti, Koi Morris
Abstract: The present invention provides methods for treating tumors of the brain by administering the compounds of the Formula A and particularly N-(3,4-dichloro-2-fluorophenyl)-7-({[(3aR,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, or a pharmaceutically acceptable salt thereof, to a subject in need of such treatment. In the methods of the invention, the compounds disclosed herein were surprisingly found to cross the blood brain barrier. The method of the present invention further relates to the treatment of cancers of any type potentially responding to EGFR, HER2, VEGFR2, or Src family kinase inhibitors and that are found in the brain.
Abstract: The invention relates to antibodies that bind to VEGFR-2. The antibodies are used for treating neoplastic diseases, hyperproliferative disorders, and angiogenic disorders and can be used alone or in combination with other agents.
Type:
Grant
Filed:
October 7, 2013
Date of Patent:
July 17, 2018
Assignee:
KADMON CORPORATION, LLC
Inventors:
Zhenping Zhu, Dan Lu, Zhanna Polonskaya
Abstract: The invention relates to inhibitors of ROCK1 and/or ROCK2. Also provided are methods of treating diseases and disorders involving inhibiting ROCK1 and/or ROCK2.
Type:
Grant
Filed:
October 7, 2013
Date of Patent:
November 14, 2017
Assignee:
Kadmon Corporation, LLC
Inventors:
Masha Poyurovsky, Ji-In Kim, Kevin Liu, Alexandra Zanin-Zhorov
Abstract: Disclosed are oral dosage forms containing a Ras antagonist including FTS and structural analogs thereof, and at least one pharmaceutically acceptable excipient other than a cyclodextrin, and methods of orally administering same to treat diseases and disorders responsive to the Ras antagonists.
Abstract: The present invention provides methods for treating or preventing viral infections using modulators of host cell enzymes relating to mTOR. The invention also provides methods for treating or preventing viral infections using modulators of host cell enzymes relating to mTOR and modulators of the unfolded protein response.
Type:
Application
Filed:
January 27, 2012
Publication date:
July 24, 2014
Applicants:
KADMON CORPORATION, LLC, THE TRUSTEES OF PRINCETON UNIVERSITY
Abstract: Disclosed are alkoxyalkyl S-prenylthiosalicylates and pharmaceutical compositions containing the same and a pharmaceutically acceptable carrier. Methods for treating a human afflicted with cancer, including solid tumors, or a hematological malignancy by administering to the human in need thereof an effective amount of an alkoxyalkyl S-prenylthiosalicylate are also disclosed.
Type:
Grant
Filed:
January 20, 2010
Date of Patent:
December 25, 2012
Assignees:
Ramot at Tel-Aviv University Ltd., Kadmon Corporation, LLC
Inventors:
Yoel Kloog, Liat Goldberg, Victor J. Bauer